eMPendium
37
Quality Score
Emerging
eMPendium
Low confidence
✍️ bumetric analysis
“
eMPendium is an iOS app from MEDYCYNA PRAKTYCZNA SP Z O O in the Education category, currently rated 3.4★ across 5 ratings. Initial signal reads as mixed reviews: supporters praise core features while critics cite stability and value gaps.
Quality Score is 37: Emerging (early traction worth watching). For a Education app, that means early traction worth watching. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
💰 Monthly revenue · now vs forecast
● Right now
$500
per month
→
12-mo forecast
$437 – $1575
per month
→
24-mo forecast
$405 – $3644
per month
INDIE tier
💡 Grow this revenue
Free AI audit of this app’s store listing
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
Typical impact: +2-5× organic installs
📊 Performance Tracking LIVE
Loading…
Rating
—
Reviews
—
Forecast Revenue / mo
—
Snapshots tracked
0
since first record
ONE-TIME · BUILD
💰 Estimated build cost
$60K
↳ What it cost to build · not monthly revenue
Likely range $45K – $80K
$25K · MVP floor
$100K · indie scale
$500K+ · studio build
📈
Slow ROI — current MRR is well below build cost
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
Where the money goes
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Education complexity ×1.20 | +$10K |
Total estimate
$60K
🔬
How we forecast this revenue
LOW CONFIDENCEBaseline
$500/mo · ML-estimated from 234 triggers
Growth rate
+6.0% MoM · INDIE tier baseline (compound monthly)
Direction
Headwinds: rating drift may slow acquisition
6 months
$426 – $993
12 months
$437 – $1.6K
24 months
$405 – $3.6K
Compound growth at +6.0% MoM (tier baseline for INDIE). Range widens with horizon — typical noise band ±40% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊
BU Investment Matrix
Pre-traction · 35/100INDIE TIERlimited signalGrowth Velocity
5.0
Founder Strength
3.2
Product Quality
2.7
Revenue Strength
2.7
Monetization Maturity
1.0
Defensibility
4.5
Market Position
2.0
Operational Safety
7.0
- 💰 Revenue: Marginal — $200 - $1250/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: 3.4★ across 5 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: last update 182d ago — slow cadence.
- ⚠️ Risk: Moderate — no material risk signals detected.
🎯 For competitors: Mixed picture. Worth competing if you have a clear UX or pricing edge — otherwise crowded segment.
💵 For acquirers: Estimated asking range 18-32× monthly = $9K-$16K.
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:
💰 Forecast Revenue / mo
MODELRevenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
🔬Forecast Breakdown — Why This Estimate?Top 4 of 4 triggers
Our ML model uses 200+ signals from public data. These are the most influential for this app:
| Below-average rating (3.4★)METRIC | −$1,500 | |
| Mature app (15y old)METRIC | +$1,500 | |
| Ad-supported / freemiumMETRIC | +$600 | |
| Pre-traction phase (5 ratings)METRIC | −$300 |
METRIC = structural app data · REVIEW = mined from user reviews · ✓ VERIFIED = Stripe-verified anchor (TrustMRR)
📈 Reviews Growth
LIVECumulative review count from first BU snapshot. Each point = a tracked update.
⭐ Rating Trend
LIVEAverage rating evolution. Updates with each new review batch.
🆕 What's New · v1.9.19
* Bug fixes
Profile & Insights
Everything we know — and don't — about this app and its company.
Identification
- App name
- eMPendium
- Developer
- MEDYCYNA PRAKTYCZNA SP Z O O
- Bundle ID
- pl.mp.empendium
- App Store URL
- Open in App Store
- Category
- Education
- Content rating
- 17+
- Languages
- PL, RU, ES, UK
Company
- Website
- Not found
- Tagline
- Not found
- Description
- Empendium is developed by Medycyna Praktyczna, a Polish medical publishing house.
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $144/mo
- Top-grossing rank
- Outside top 100 in US Education
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Founder data not yet collected for this app.
Funding
Funding data not yet collected for this app.
Press & Links
Press & Links data not yet collected for this app.
Contacts & Socials
- Socials
- Not found
- empendium@mp.pl
- Phone
- +48 12 293 40 08
- Contact page
- Not found
- About page
- Not found
📈Ratings growth5 ratings+400% lifetimeShow 3-year history estimate ▾
Tracked (6 weeks) Pre-tracking estimate (37 weeks) · model-based, ±5% noise · anchored to release date and current value
🌍Geographic ReachNot ranked
This app is currently outside the top 100 grossing in all 9 countries we monitor (US, UK, DE, FR, JP, CA, AU, BR, IN). Niche or new apps often launch this way — popularity rankings appear once daily revenue clears the regional threshold.
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.
📝 About this app
Modular application containing:
*Leki* - (Drug Module) - free; Comprehensive Polish Drug Reference, developed by the Medycyna Praktyczna editorial board. Updated daily!
Reliable drug descriptions, prices, current availability on the Polish market and much more. The drug database contains:
- over 7,000 drug descriptions
- over 1,400 drug active components descriptions
- over 10,000 drug items with prices
The module content is restricted to registered users of Medycyna Praktyczna website (mp.pl).… View full description on the official store →
*Leki* - (Drug Module) - free; Comprehensive Polish Drug Reference, developed by the Medycyna Praktyczna editorial board. Updated daily!
Reliable drug descriptions, prices, current availability on the Polish market and much more. The drug database contains:
- over 7,000 drug descriptions
- over 1,400 drug active components descriptions
- over 10,000 drug items with prices
The module content is restricted to registered users of Medycyna Praktyczna website (mp.pl).… View full description on the official store →
App Specs
🔐 Own this app? Claim & verify MRR →💾 17 MB🔞 17+📱 iOS 13+🔖 v1.9.19🔄 updated 0d ago🌐 PL, RU, ES, UK📂 Education💰 Paid
📅
What Worked™ · Development Pipeline
6 EVENTS TRACKEDDetected changes in this app over its tracked lifetime — each event links cause (what changed) to effect (what moved). Sorted newest first.See full history →Version history →
2026-05
⭐
Rating ↓ 4.80 → 3.40 (dropped 1.40★)
2026-05
🔄
Monetization changed: freemium → free
2026-03
⭐
Rating ↑ 4.00 → 4.80 (improved 0.80★)
2026-03
📈
Crossed 10 ratings — social-proof flywheel kicking in
2025-03
⭐
Rating ↓ 5.00 → 4.00 (dropped 1.00★)
2012-06
🚀
First tracked snapshot — initial data captured
🌍
Multi-Country Performance
Available in 9 of 9 monitored markets| Market | Rating | Reviews | Current version |
|---|---|---|---|
| 🇦🇺 AU | 0★ | 0 | — |
| 🇧🇷 BR | 5★ | 1 | 5★ this version |
| 🇨🇦 CA | 0★ | 0 | — |
| 🇩🇪 DE | 5★ | 3 | 5★ this version |
| 🇫🇷 FR | 0★ | 0 | — |
| 🇬🇧 GB | 5★ | 2 | 5★ this version |
| 🇮🇳 IN | 0★ | 0 | — |
| 🇯🇵 JP | 0★ | 0 | — |
| 🇺🇸 US | 3.4★ | 5 | 3.4★ this version |
🔔
Track this app’s revenue
FREEGet an email when revenue moves by your threshold. No spam, unsubscribe in one click.
📝 Description
95
BU Score · Transcendent
About this analysis
Why low confidence: only 5 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
📌 Final verdict — read this before you trust the numbers above
eMPendium is a early-stage iOS app in the education space with weak public traction — only 5 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.
❓ Frequently Asked Questions
4 answers · auto-generated from this app's public dataHow much does eMPendium make per month?▴
Low-confidence model estimate. eMPendium has only 5 App Store ratings, so our revenue model has very little signal to work with — treat the ~$143/mo figure as directional only, not a verified MRR. No founder-verified revenue data is available for this app. See methodology for the formula and confidence bands.
What apps are like eMPendium?▴
Browse the full Education category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
Who makes eMPendium?▴
eMPendium is published by MEDYCYNA PRAKTYCZNA SP Z O O on the Apple App Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.
What is eMPendium's BU Score?▴
eMPendium has a BU Score of 37/100 (Emerging). The score combines App Store rating, ratings count, monetization model and revenue signals calibrated against founder-verified MRR anchors. See the BU Score formula.